SCHEMBL948677

SCHEMBL948677

CN1CCN(C(=O)c2c[nH]c3ccccc23)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.71
HTT P42858 1/20 0.66
MAPK14 Q16539 1/20 0.66
DRD2 P14416 1/20 0.61
DRD3 P35462 1/20 0.61
AVPR1A P37288 1/20 0.58
HDAC1 Q13547 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
PBRM1 Q86U86 1/20 0.55
GABRA1 P14867 2/20 0.55
GABRG2 P18507 2/20 0.55
GABRB3 P28472 2/20 0.55
GABRA3 P34903 2/20 0.55
GABRA2 P47869 2/20 0.55
GABRB2 P47870 2/20 0.55
POLB P06746 1/20 0.55
GPR84 Q9NQS5 1/20 0.54
RAB9A P51151 1/20 0.54
CCR5 P51681 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9410743 0.85 GFER (0.71) GFERHTTMAPK14DRD2DRD3
SCHEMBL289605 0.85 POLB (0.74) GFERHTTMAPK14AVPR1AHDAC1
SCHEMBL29335990 0.85 MAPK14 (0.73) GFERHTTMAPK14DRD2DRD3
SCHEMBL1553347 0.84 GFER (0.65) GFERHTTMAPK14DRD2DRD3
SCHEMBL28481273 0.84 GFER (0.68) GFERHTTMAPK14DRD2DRD3
SCHEMBL1144650 0.84 GFER (0.68) GFERHTTMAPK14DRD2DRD3
SCHEMBL8445235 0.83 GFER (1.00) GFERHTTMAPK14DRD2DRD3
SCHEMBL8984788 0.83 GFER (0.67) GFERHTTMAPK14DRD2DRD3
SCHEMBL8707863 0.82 GFER (0.67) GFERHTTMAPK14DRD2DRD3
SCHEMBL20181880 0.82 ALDH1A1 (0.75) GFERHTTMAPK14DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101544592-B Process for preparation of N-arylsulfonyl-3-substituted indoles SUVEN LIFE SCIENCES LTD 2013-08-21 CN disclosed
CN-1720225-B N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LTD 2011-05-18 CN disclosed
US-7875605-B2 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea SUVEN LIFE SCIENCES LIMITED (IN) 2011-01-25 US disclosed
CN-101544592-A N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LTD (IN) 2009-09-30 CN disclosed
EP-1581492-B1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2008-07-16 EP disclosed
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them SUVEN LIFE SCIENCES LIMITED (IN) 2006-10-05 US disclosed
CN-1720225-A N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LTD (IN) 2006-01-11 CN disclosed
EP-1581492-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Suven Life Sciences Limited (IN) 2005-10-05 EP disclosed
WO-2004048330-A1 N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
EP-0922042-A1 NOVEL PIPERAZINE CONTAINING COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1999-06-16 EP disclosed
WO-1998006715-A1 NOVEL PIPERAZINE CONTAINING COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223890-A1 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them HTR3A, HTR3C, HTR2C GFER 918/4885HTT 284/4885MAPK14 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.